Molecular Pathology and Tissue Resource

点击翻译按钮获取中文摘要

Pathology Core (Core B) Project Summary/Abstract The Molecular Pathology and Tissue Resources Core will provide routine and innovative tissue resources and materials essential for achieving the aims of the SPORE projects. Routine materials include tumors, non- malignant lung specimens, tumor cell lines, and clinical annotation, all of which have been obtained with informed consent and measures to ensure patient confidentiality. Over 6,000 tumors including tumors on clinically annotated tissue microarrays (TMAs), 300 lung cancer cell lines of all histologic types, and over 180 lung tumor patient-derived and circulating tumor cell-derived xenografts (PDXs/CDXs) are available to investigators. Many of these samples have been distributed to our SPORE investigators, as well as other investigators at our own and outside institutions (including other SPOREs). These partnerships have fueled multiple lung cancer translational research collaborations, and have generated over 380 publications in the last ten years. In addition to important clinical and histologic annotation, the genomic, molecular, and immune microenvironment profiling of these samples provide important Human Endpoints for correlative data and synergy, both within the UT Lung SPORE and as components of other lung cancer translational research. Given the increasing importance of immunotherapy for lung cancer, the Pathology Core has developed methods to provide state of the art immune profiling annotation. Additionally, the Core has participated in collection of patient samples from the MDACC ImmunogenomiC prOfiling of NSCLC (ICON) and NEOadjuvant STudy of induction checkpoint blockade for Resectable stage I-IIIA NSCLC (NEOSTAR) clinical trials. Our Aim 1 is to collect, process, store, catalog and distribute tissues, cell lines and blood specimens, both malignant and non- malignant, tumor xenografts, and relevant clinico-pathologic and molecular data, as requested by the various component projects of the SPORE program; we will use IRB-approved protocols, informed consent, and measures to protect subject confidentiality. Aim 2 is to develop and utilize innovative and routine tissue and cell line resources that will aid in the successful completion of the SPORE program aims; these include development of new tumor cell lines, additional lung cancer TMA resources, molecular analysis of tumors and liquid biopsy, and comprehensive immune profiling of tissues. Aim 3 is to perform, interpret, analyze, and deposit tissue-based molecular and immune analysis methodologies in close collaboration with the component Projects, DRP, CEP, and Data Sciences Core of the SPORE program to achieve their approved aims. Within these aims, the Pathology Core will play a crucial role in promoting vertical and horizontal collaborations among our own SPORE investigators, investigators at other Lung Cancer SPORE sites, and other investigators at our own and other institutions. All of our SPORE projects will use Core B materials and services. Heavy utilization of our routine and innovative materials, as well as close interactions with the SPORE investigators, will greatly aid the successful completion of the aims of our SPORE proposal.